Pharmaceutical Product Develop (PPDI) Income Statement

Click line-items for a historical chart and %

Service revenue	382.87M
Reimbursed revenue	32.52M
Total net revenue	415.4M
Direct costs	223.51M
Research and development expenses	2.07M
Selling, general and administrative expenses	107.58M
Depreciation and amortization	16.82M
Total operating expenses	349.98M
Operating income	65.42M
(Loss ) income from equity method investment	1.92M
Gain (loss) on Investments	-17.7M
Other income (expense), net	1.07M
Income from continuing operations before provision for income taxes	50.7M
Provision for income taxes	15.08M
Income from continuing operations	35.62M
Loss from discontinued operations, net of income taxes	0
Net income	35.62M
Net loss attributable to noncontrolling interests	-181K
Net income attributable to shareholders	35.44M
Basic	0.31
Diluted	0.31
Basic and diluted loss per common share from discontinued operations	0
Basic	0.31
Diluted	0.31
Dividends declared per common share	0.15
Basic	113.89M
Dilutive effect of stock options and restricted stock	1.3M
Diluted	115.19M

Entities mentioned with PPDI

View All Entities